About Us
Corporate Offices
| US Headquarters | European Headquarters |
| Patheon Inc. PO Box 110145 Research Triangle Park, NC 27709-5145 P: 919.226.3200 F: 919.474.2269 |
Patheon International AG Lindenstrasse 14 6340 Baar Switzerland P: +41 41 766 2580 F: +41 41 766 2581 |
Capabilities Overview
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through the commercial manufacturing of a wide array of dosage forms including parenteral, solid, semi-solid and liquids.
Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical supplies, scale-up and commercialization. Patheon's ability to integrate development and manufacturing services ensures that our customers' projects are delivered on time and meet the high standards of quality that Patheon is known for.
Patheon's integrated development and manufacturing network of 10 facilities and 7 development centers, across North America and Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.
Commercial Manufacturing Services
Patheon's commercial manufacturing dosage capabilities:
- Solids in tablets, capsules, and powders
- Liquids & Semi-Solids Capabilities
- Sterile Products Capabilities
- Lyophilization Capabilities
- High Potency Capabilities
- Controlled Substances Capabilities
- Cephalosporin Capabilities & Lyophilization
- Solutions, suspensions, sprays and gels
- Liquid Filled Hard Capsules
- Cytotoxics
Commercial Manufacturing for Specialized Services
- Quick to Market™
- Restructuring Services
- Small Scale Commercial Manufacturing
Pharmaceutical Development Services
- Pre-formulation
- Analytical Methods
- Scale up & Validation
- Biopharmaceutical
- Product Registration
- Tech Transfer
Specialized Development Services
- Unique Dosage Forms
- Quick to Clinic™
- Strategic Alliances
- Clinical Supplies
Clinical Supplies
- Primary and secondary clinical supplies packaging
- Blinded & multi-language labeling
- Storage
- Global distribution
- Returns
- Reconciliation and destruction
Enhanced services provided by Patheon:
.jpg)
QUICK TO CLINIC™
Patheon offers Quick to Clinic™ programs focused on bringing new molecules to FTIH studies as rapidly as possible while minimizing the amount of API required. Patheon uses the experience and scientific knowledge of its team of Pharmaceutical Development Services (PDS) scientists combined with a number of tools and strategies to achieve these results.
Quick to Clinic™ Dosage Forms:
- Blend in capsule
- API in capsule
- Blend in bottle
- API in bottle
- Tablets
- Oral solutions
Why use Patheon's Quick to Clinic™ service?
- Fast, Flexible, Proven
- Delivery in 4 Months
- Specialized early phase development centers
- Global Network
- No scheduling competition with late phase projects
- Simple, fit for purpose formulations
- Blend in capsule
- API in capsule
- Blend in bottle
- API in bottle
- Tablets
- Oral solutions
.jpg)
The ‘4•6•8 Promise™'
The Quick To Market™ program also introduces its ‘4•6•8 Promise™'. The term is used to highlight the benefits of its rapid development / rapid transfer programs by emphasizing to clients how quickly the work can be done by Patheon while maintaining the high standards of quality that Patheon is known for. The ‘4•6•8 Promise™', as it is now called, is more adequately described as follows:
- 4: Quick To Clinic™ solid dose molecules will be formulated and ready for distribution to phase 1 clinical trials in just four months from receipt of API.
- 6: Quick To Market™ solid dose or liquid products will be transferred and ready for regulatory filing in just six months from receipt of analytical methods and API. This enables clients to move products very quickly out of their plants and facilitate rationalization programs.
- 8: Quick To Market™ aseptic liquid or lyophilized sterile products will be ready for regulatory filing in just eight months from receipt of analytical methods and API.
.jpg)
•Datasheet: Quick To Clinic™
•Datasheet: Quick to Market™
•Datasheet: 4.6.8 Promise™
•Datasheet: Early Formulation Development
•Datasheet: Pharmaceutical Analytical Development
•Datasheet: Clinical Supplies Services
•Datasheet: Business Management
•Datasheet: Oral Dose Contract Manufacturing
•Datasheet: Pharmaceutical Drug Delivery
•Datasheet: Sterile Contract Manufacturing
•Datasheet: Biopharmaceutical Contract Manufacturing
•Datasheet: High Potency Contract Manufacturing
•Datasheet: Pediatric Formulation Development
•Datasheet: Clinical Supplies Services
•Datasheet: Cephalosporin Contract Manufacturing
•Datasheet: Puerto Rico Facility
•Datasheet: Small Scale Commercial Manufacturing
•Datasheet: Low Solubility Compounds
•Datasheet: Cytotoxic Contract Manufacturing
•Datasheet: Lean 6 Sigma
•Datasheet: Roller Compaction
Contact Information
Patheon Inc.
P.O. Box 110145
Research Triangle Park, NC
UNITED STATES
Contact: doingbusiness@patheon.com
Hot Products
- SoluPath™
- SoluPath™ – The First Fixed-Price, Multi-Platform Solution To Improve Bioavailability
- Quick To Clinic™
- Quick To Market™
- 4.6.8 Promise™
- Pre-Formulation & Formulation Development
- Pharmaceutical Analytical Development
- Pharmaceutical Contract Clinical Packaging
- Scale-Up And Registration Support
- Scientific Expertise
- Project Management
- Customer Development Pipeline
- Specialized Services
- Conventional Dosage Form Development
- Controlled Release Formulations
- Steriles Development & Manufacturing
- Lyophilization Development
- Biopharmaceutical Development & Manufacturing
- Disposable Technologies
- Liquid-Filled Hard Capsules (LFHC)
- High Potency Contract Manufacturing
- PatheonPartner.com™
- Pediatric Formulation Development
- Clinical Trial Materials (CTM) Manufacturing
- Customer Launches
- Patheon Restructuring Services
- Cephalosporin Contract Manufacturing
- Customer Management
- Pharmaceutical Contract Packaging
- Solid Dose Contract Manufacturing
- Liquid/Semi-Solid Contract Manufacturing
- Contract Manufacturing: Nasal Sprays
Featured Articles
- Patheon Reports Third Quarter Results
- Patheon reports third quarter results
- Patheon Reports Second Quarter Results
- Patheon Reports Fourth Quarter Results
- Patheon Reports First Quarter 2009 Results
- Patheon Inc. To Exhibit At INTERPHEX In New York City
- Patheon Completes Purchase of European Pharmaceutical Plants
- Patheon completes agreement with Novartis for long term supply contracts and purchase of Canadian pharmaceutical manufacturing plant
- Patheon Announces Completion Of MOVA Pharmaceutical Acquisition
- Paetheon raises additional $5.8 million from over-allotment stock sale
- Merck & Co., Inc. Selects Patheon As Strategic Supplier
- Clive V. Bennett Appointed President, Patheon U.S.A.
- Strategic Outsourcing in the Pharmaceutical Industry
- Patheon Will Acquire Two European Pharmaceutical Plants
- Patheon To Purchase Pharmaceutical Plant in UK; Positions Company to Play a Strong Role in European Pharmaceutical Manufacturing Market
- Patheon to Purchase Pharmaceutical Plant in France; Solidifies Company's Position in European and Global Pharmaceutical Manufacturing Markets
- Patheon to provide development & commercial manufacturing services for needle-free drug delivery system
- Patheon Special Committee Engages Advisors To Prepare For Unsolicited Bid From JLL
- Patheon Signs Three Year $18M Development Agreement With Boehringer Ingelheim
- Video: Patheon At AAPS 2010
- Managing CMOs With Complementary Capabilities
- Patheon Adds Softgel Capsule Capability At Its Cincinnati Facility
- Patheon Inc. To Present At The 20th Annual UBS Global Healthcare Services Conference
- Patheon To Build Pharmaceutical Development Center In Bourgoin, France
- Patheon Inc. To Present At The Jefferies 2010 Global Healthcare Services Conference
- Peter T. Bigelow Joins Patheon As President, North American Operations
- Patheon Inc. Signs Two 5-Year Manufacturing Agreement Renewals With Sanofi-Aventis
- Patheon Inc. To Present At J.P. Morgan Healthcare Conference
- Patheon Reports Fourth Quarter And Full Year Fiscal 2009 Results
- Notice Of Cancellation Of December 15, 2009 Special Meeting Of Shareholders Of Patheon Inc.
- Patheon Inc. Announces Manufacturing Consolidation In Puerto Rico
- Patheon Announces Date Of Fourth Quarter And Full Year 2009 Financial Results Release And Conference Call
- Patheon, Inc. Announces The Appointment Of Francisco R. Negron As Vice President And General Manager Of Its Puerto Rico Operations
- Patheon, Inc. Adds Two Key Industry Leaders To Its Pharmaceutical Development Services Business
- Patheon Inc. Features Its Manufacturing Performance Guarantee At Upcoming CPhl Worldwide Conference
- Patheon Reports Third Quarter 2009 Results
- Patheon Continues To Explore US$3.55 Lonza Proposal Special Committee Responds To JLL Statements After Expiry Of Inadequate Bid
- Lonza Group AG Submits Non-Binding Proposal To Acquire All Patheon Inc.
- Patheon's Puerto Rico Site Receives European Regulatory Approval
- Patheon Special Committee Notes Continued Shareholder Resistance To JLL’s Inadequate And Coercive Offer
- Patheon Signs Global Service Agreement With Sodexo
- Patheon Announces Appointment Of New Chairman Of The Board
- Court Rejects JLL Application, Upholds Election Of Patheon Independent Directors
- Patheon Signs Facilities Management Agreement With Emcor Group, Inc. Subsidiary
- Patheon Reports Second Quarter 2009 Results
- Patheon Inc. Extends Its Sterile Filling Capabilities To Include The Commercial Supply Of Small Scale Specialty Products
- Patheon Inc. Announces Its Performance Guarantee
- Patheon Inc. Recognized By Eli Lilly And Company As A Key Supplier
- Patheon Inc. Names Interim Head Of Pharmaceutical Development Services Unit And Chief Scientific Officer
- Patheon Commences Legal Action Against JLL And Responds To Dissident Requisition
- Patheon Announces Date Of Second Quarter 2009 Financial Results Release, Conference Call And Webcast
- Patheon Inc. Adds Capability To Conduct Cell Based Assays
- Patheon Confirms Receipt Of Requisition For Special Meeting Of Shareholders
- Patheon Inc. Corrects Reported Voting Results Of Its 2009 Annual Meeting Of Shareholders
- Patheon Announces Results Of 2009 Annual Meeting Of Shareholders
- Patheon Board Of Directors Confirms Recommendation That Shareholders Reject Inadequate JLL Offer
- Patheon Inc. Signs Agreements To Commercialize OROS-Based Controlled Release Products
- Patheon Inc. Expands Toronto Facility, Creates Dedicated Space For Oral Contraceptives Production
- Patheon Signs Strategic Alliance Agreement With Kemwell
- Patheon Signs Agreement With Swiftwater Group To Expand Regulatory Consulting Services
- Patheon Announces Date Of First Quarter 2009 Financial Results Release, Conference Call And Webcast
- Patheon Announces Closing Of Carolina Facility
- Patheon Opens New U.S. Headquarters And Analytical Laboratory Facility In Research Triangle Park, NC
- Patheon Acknowledges Proposed Bid By JLL To Acquire All Outstanding Shares
- Patheon And Senopsys Announce Alliance
- Patheon Launches Quick To Market Program To Industry Program Introduces The “4•6•8 Promise”
- Patheon Launches Quick To Clinic Program
- Patheon And Omnicare Clinical Research Sign Agreement For Clinical Distribution In Europe And Asia Pacific
- Patheon Provides AcuForm™ Technology To Its Customers Through Ongoing Partnership With Depomed™
- Patheon Establishes European Headquarters In Switzerland
- Patheon Expands PDS Capacity In Canada
- Patheon Completes Intermediate Scale Processing Facility At Its Cincinnati Plant
- Patheon Reaches Agreement With BSP Pharmaceuticals For Development And Manufacture Of Cytotoxics
- Patheon Announces Official Opening Of Milton Park Early Phase Development Center In Oxfordshire, UK
- Patheon Establishes Headquarters And Development Services Laboratory In Research Triangle Park, North Carolina